Eisai Innovation
- Company typePrivate
- Founded2019
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Eisai Innovation firmographics
Firmographics- Name
- Eisai Innovation
- Legal name
- Eisai Innovation Inc.
- Website
- https://eisaiinnovation.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Eisai Innovation industry classification
Industry- Product category
- Corporate Venture Capital / Strategic Healthcare Investment
- NAICS
- Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
- SIC
- Finance Services (6199), Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Eisai Innovation is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Eisai Innovation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Investment Returns: Eisai Innovation generates returns through equity investments in early-stage biotech and digital health companies. Returns are realized through portfolio company exits via IPOs, acquisitions, or strategic transactions. The investment thesis focuses on creating synergy with Eisai's core business in neurology and oncology.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Eisai Innovation product offering
Product offeringCore offering
Eisai Innovation Inc. is a corporate venture capital (CVI) organization and strategic investment arm of Eisai Co., Ltd. It makes equity investments of approximately $5 million USD per deal into early-stage biotech and digital health companies focused on neurology, oncology, diagnostics, and digital healthcare solutions, with an approximately 10-year exit horizon across US, Europe, Japan, China, and emerging markets including Africa.
Product overview
Eisai Innovation Inc. is a strategic investment organization and Corporate Venture Capital (CVI) arm of Eisai, a global pharmaceutical company headquartered in Japan. Rather than offering products or services, the company identifies synergies between the scientific community and the Eisai network through investments in biotech and digital health companies. The investment focus areas include Neurology, Oncology and their digital solutions, and Diagnostics, with investments of approximately $5 million USD per deal across US, Europe, Japan, China, and emerging markets including Africa, with an approximately 10-year exit timeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Corporate Venture Capital (CVI) Investment Program Equity investment program targeting early-stage biotech and digital health companies in neurology, oncology, diagnostics, and digital healthcare solutions, with investment size of approximately $5 million USD per deal and ~10 year exit horizon. For portfolio company founders and academic spinouts.
Companies that use Eisai Innovation
Customer profileSegments1 record
Ideal customer profiles2 records
Eisai Innovation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Eisai Innovation partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights5 records
Eisai Innovation competitors and assessment
Company assessmentDirect peers
- AbbVie Ventures: AbbVie's corporate venture arm focused on therapeutic areas aligned with the parent. Directly comparable as a pharma CVC using equity investments to source strategic innovation.
- SR One (GSK): GSK's venture capital arm investing in biotech and healthcare innovation globally. Mirrors Eisai Innovation's CVC model, global investment footprint, and therapeutic-area alignment with the parent.
- Bayer Leaps by Bayer: Bayer's impact-oriented venture arm investing in breakthrough health and agricultural biotech. Comparable as a global pharma CVC with biotech focus and a strategic, long-horizon approach similar to Eisai Innovation.
- Amgen Ventures: Amgen's corporate venture capital arm investing in early- to mid-stage biotech companies. Comparable to Eisai Innovation as a pharma CVC pursuing strategic alignment with the parent's R&D priorities.
- Pfizer Ventures: Pfizer's dedicated corporate venture capital arm investing in early-stage biotech and healthcare companies. Directly comparable to Eisai Innovation as a pharma CVC pursuing strategic investments aligned with the parent's therapeutic priorities.
- Sanofi Ventures: Sanofi's corporate venture fund focused on early-stage biotech and digital health. Closely analogous to Eisai Innovation in mandate (early-stage, strategic, ~$5M checks) and parent-backed structure.
- Novartis Venture Fund: Corporate venture arm of Novartis investing across biotechnology with multi-stage tickets and a global footprint. Mirrors Eisai Innovation's model of a global pharma CVC with patient capital and strategic alignment to the parent.
- Roche Venture Fund: Roche's CVC investing in early-stage diagnostics and therapeutics. Directly comparable as a pharma CVC with therapeutic focus and long investment horizon, sharing the same strategic-M&A exit logic as Eisai Innovation.
Broad incumbents
- Bristol Myers Squibb (Innovation & BD): BMS conducts equity investments and partnerships through its business development arm rather than a standalone CVC fund. Comparable as a major pharma investor in early-stage biotech and oncology assets, though structurally distinct from a pure CVC.
- Eli Lilly (Magnolia Bend Capital / Strategic Investments): Lilly pursues CVC-style investments and partnerships across biotech and digital health. Comparable as a global pharma deploying strategic capital into early-stage therapeutic innovation, with overlapping portfolio themes (neurology, oncology, digital health).
Market position
Weaknesses4 records
Competitive moat5 records
Key risks2 records
Key highlights7 records
Customer concentration
Eisai Innovation social profiles
Digital presenceEisai Innovation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eisai Innovation leadership team
Management profileNumber of profiles
Profiles3 records
Eisai Innovation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eisai Innovation M&A and investment
M&A and investmentM&A
Investments12 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eisai Innovation
What does Eisai Innovation do?
Eisai Innovation Inc. is a corporate venture capital (CVI) organization and strategic investment arm of Eisai Co., Ltd. It makes equity investments of approximately $5 million USD per deal into early-stage biotech and digital health companies focused on neurology, oncology, diagnostics, and digital healthcare solutions, with an approximately 10-year exit horizon across US, Europe, Japan, China, and emerging markets including Africa.
Is Eisai Innovation a public or private company?
Eisai Innovation is a private company. It is classified as corporate owned and is currently operating.
When was Eisai Innovation founded?
Eisai Innovation was founded in 2019. It employs 1 to 10 people.
Where is Eisai Innovation based?
Eisai Innovation is headquartered in Cambridge, United States, in the North America region.
How does Eisai Innovation make money?
One revenue line is on record: investment Returns.
Who are Eisai Innovation's main competitors?
Direct peers on record are AbbVie Ventures, SR One (GSK), Bayer Leaps by Bayer, Amgen Ventures, Pfizer Ventures, Sanofi Ventures, Novartis Venture Fund and Roche Venture Fund. Broad incumbents are Bristol Myers Squibb (Innovation & BD) and Eli Lilly (Magnolia Bend Capital / Strategic Investments).
Does Eisai Innovation have an API?
No public API is recorded for Eisai Innovation.
What industry is Eisai Innovation in?
Eisai Innovation's product category is Corporate Venture Capital / Strategic Healthcare Investment. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52394 and its SIC code is 6199.